Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2024 call → NOThe question asks whether management describes that successive engagements of the same kind are coming in at progressively larger size — that is, whether the deals/orders/projects/customers/sites/programs being landed now are individually bigger, broader, or longer than before for the same offering. Let me scan the transcript for any such description. Key points from the call: - Record revenue of $41.2M, up 25% YoY - Smart grid customer: "we received our first follow-on order for the first half of fiscal year 2025 as this customer is transitioning from design and initial production to a run rate business." The follow-on order is around $11 million to be delivered in the first half. - The initial ramp was ~$20 million in Q4 fiscal 2024. - Saleel says: "we expect the business will continue to grow over time. That said, I'm very pleased that we received our first follow-on order even though they are just at the beginning of the deployment, and the initial order is around $11 million to be delivered in the first half, as they've also gone to a run rate sort of business." So the follow-on order is $11M for the first half of fiscal 2025, while the current quarter (Q4 FY24) is ~$20M. So the follow-on order is actually smaller than the current quarter's shipment. The $11M is for the first half (two quarters), so roughly $5.5M per quarter, which is much smaller than the $20M quarter. Is there any description of deals getting progressively larger? The follow-on order is smaller than the current ramp. There's no statement that new orders are bigger than before. The company talks about growth, but not about escalation of unit size. The question asks about "successive engagements of the same kind coming in at progressively larger size." Here, the follow-on order is actually smaller than the current quarter's shipments. There's no comparison against the company's own past showing escalation. Also, the company says it expects the business to grow over time, but that's not about deal size escalation. No mention of average order size stepping up, customers starting at broader scope, etc. So the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.